gutflix
GI learning, personalised

Summary

UPADACITINIB IN CONCURRENT SEVERE ATOPIC DERMATITIS, ALOPECIA AREATA AND CROHN'S DISEASE: A CASE REPORT

Francesca Ambrogio

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A case report describes a 28-year-old male with treatment-refractory atopic dermatitis, alopecia areata, and Crohn's disease who showed improvement in all three conditions following off-label treatment with upadacitinib.

KEY POINTS

- The patient had severe atopic dermatitis (EASI 45.1), complete alopecia areata (SALT 100), and Crohn's ileocolitis with severe recurrence (Rutgeerts i3), all refractory to multiple prior therapies including biologics.
- Upadacitinib 30 mg daily was initiated for atopic dermatitis and alopecia areata (not approved for Crohn's disease); dose was reduced to 15 mg daily at 3 months due to acneiform facial eruption.
- At 9 months, dermatological scores improved substantially (EASI 1, SALT 0), colonoscopy showed normal ileal mucosa, and contrast-enhanced ultrasonography demonstrated complete resolution of bowel inflammation with Limberg score 0.
- Gastrointestinal symptoms including stool frequency, abdominal pain, and urgency improved during treatment.
- The authors describe this as the first report of successful upadacitinib treatment in a patient with all three concurrent conditions.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/c8538f32-743b-11ee-9965-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.